Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) for Patients With Relapsed/Refractory Aggressive B Cell Lymphomas

NCT02747732 is registered in ClinicalTrials.gov with Meirav Kedmi MD as lead sponsor.

NCT NCT02747732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02747732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) for Patients With Relapsed/Refractory Aggressive B Cell Lymphomas
Lead sponsor
Meirav Kedmi MD
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2016
Completion date
October 31, 2021
Enrollment
72 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, primary mediastinal (thymic) large b-cell lymphoma, recurrent disease, refractory cancer, transformed indolent lymphoma